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Abstract
The molecular characteristics of thiamin (T) transport were studied in the small intestinal and renal brush border
membrane vesicles of rats, using [3H]T at high specific activity. The effects of various chemical modifiers (amino acid
blockers) on T uptake were examined and their specificity assessed. Treatment with the carboxylic specific blockers
1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate, (1-ethyl-3-[3-(dimethylamino)propyl]-carbodi-
imide hydrochloride and N-ethyl-5-phenylisoaxolium-3P-sulfonate (Woodward’s Reagent K) and with the sulfhydryl specific
blocker p-chloromercuribenzene sulfonate inhibited T transport in both types of vesicles. Phenylglyoxal, but not ninhydrin,
both reagents for arginine residues, and diethylpyrocarbonate, a reagent for histidine residues, specifically decreased T
transport only in renal and small intestinal vesicles respectively. Similarly 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole reacted,
but not N-acetylimidazole, both of which are reagents for tyrosine residues. However, 7-chloro-4-nitrobenzo-2-oxa-1,3-
diazole inhibition was aspecific. Acetylsalicylic acid, a reagent for lysine and serine residues, decreased T transport, but the
lysine effect was aspecific. Acetylsalicylic acid serine blockage also eliminated T/H exchange in small intestinal vesicles.
Taken together, these results suggest that for T transport carboxylic and sulfhydryl groups and serine residues are essential in
both renal and small intestinal brush border membrane vesicles. In addition, arginine and histidine residues are also essential
respectively for renal and small intestinal transporters. Serine was essential for the T/H antiport mechanism. ß 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
Thiamin (T) entry into rat enterocytes, as eval-
uated in brush border membrane vesicles (BBMVs),
is a saturable, carrier mediated process at low (phys-
iological) concentrations [1,2], which is Na and K
independent and involves a T/H antiport mecha-
nism [3], inhibited by T analogs and derivatives.
T plasma level is, in part, regulated, like that of
other organic cations, by the kidney. At high plasma
levels organic cations are actively secreted [4], where-
as at low plasma levels they can be actively reab-
sorbed [5,6]. T in rat plasma is not protein bound
[7^9] and, under normal conditions, is reabsorbed,
rather than secreted by the proximal tubule [10]. Re-
cently a T/H exchange mechanism has been identi-
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¢ed in rat renal BBMVs [11], with features resem-
bling those of rat enterocytes.
The molecular characteristics of T microvillous in-
testinal and renal transporters have been little inves-
tigated. Komai and Shindo [12], using everted ring
segments of the rat small intestine, put forward a pre-
liminary hypothesis about the structure of the T trans-
port system. On the basis of their results, both the
amino group and the quaternary nitrogen atom of
the vitamin have been recognized as being required
for T transport, with 2P-methyl and 5-hydroxyethyl
groups signi¢cantly in£uencing T binding to the car-
rier. Iwashima et al. [13] found a T binding protein
located in the cytoplasmic membrane of yeast cells.
Chemical modi¢cation of this protein suggests that
an ionic interaction between a carboxyl residue and
a quaternary nitrogen atom of the thiazole moiety of
the T molecule could be involved in T binding to the
protein. Recently this transporter has been cloned [14].
In the present study, we chemically modi¢ed some
amino acid residues exposed to the right-side-out
BBMVs of the rat small intestine and kidney, and
examined the consequences on T transport. Prelimi-
narily, the e¡ect of various chemical modi¢ers on
T uptake by intestinal and renal BBMVs was eval-
uated. The modi¢ers used were: CMC (1-cyclohexyl-
3-(2-morpholinoethyl) carbodiimide metho-p-toluene
sulfonate), EDC (1-ethyl-3-[3-(dimethylamino)-
propyl]-carbodiimide hydrochloride) and WRK (or
Woodward’s Reagent K, N-ethyl-5-phenylisoaxo-
lium-3P-sulfonate) for carboxylic groups; PCMBS
(p-chloromercuribenzene sulfonate) and DTNB
(5,5P-dithiobis (2-nitrobenzoic acid)) for sulfhydryl
groups; PGO (phenylglyoxal) and NIN (ninhydrin)
for arginine residues; DEPC (diethyl pyrocarbonate)
for histidine residues; NAI (N-acetylimidazole) and
NBD-Cl (7-chloro-4-nitrobenzo-2-oxa-1,3-diazole)
for tyrosine residues; PLP (pyridoxal 5P-phosphate)
and SAL (acetylsalicylic acid) for lysine and serine
residues. Successively the speci¢city of action of each
chemical modi¢er was also examined.
2. Materials and methods
2.1. Animals
Adult Wistar albino rats (250^300 g body weight)
of either sex, reared on a complete standard diet
containing 12 Wg/g T [15], were used. Animals were
killed by decapitation after 12 h fasting with water
ad libitum.
2.2. Preparation of BBMVs
Intestinal BBMVs were prepared from the duode-
nal and jejunal mucosa of six adult rats using a
Mg2/EGTA precipitation method as described by
Rindi and Laforenza [16]. This method gives a lower
puri¢cation, but it does not modify proton conduc-
tance [17]. All procedures were carried out at 0^4‡C.
The purity of the microvillous membrane was esti-
mated by assessing the enrichment in alkaline phos-
phatase and K-phosphatase activities of BBMVs,
determined according to Murer et al. [18], as com-
pared to the initial mucosal homogenate. The enrich-
ment of BBMVs was 15.1 þ 1.3 for alkaline phos-
phatase, and 1.6 þ 1.2 for K-phosphatase (mean þ
S.E.M. of ¢ve di¡erent preparations).
Renal BBMVs were prepared from the kidney cor-
tex of ¢ve or six rats using the Mg2/EGTA precip-
itation method of Biber et al. [19]. The enrichments
were 15.5 þ 0.8 for alkaline phosphatase, and
1.6 þ 0.3 for K-phosphatase (mean þ S.E.M. of ¢ve
di¡erent preparations).
Protein content was measured according to Lowry
et al. [20], using bovine serum albumin as a standard.
2.3. Transport e⁄ciency of BBMVs
The transport e⁄ciency of the small intestinal and
renal vesicular preparations was evaluated by deter-
mining the time course pro¢le of D-glucose uptake
after incubation with 80 WM D-[U-14C]glucose (spe-
ci¢c activity, 0.31 GBq/mmol) as described by Casir-
ola et al. [2]. The time course pro¢le of D-glucose
uptake in the presence of an initial 100 mM NaCl
gradient (outs in) showed an overshoot at 6^45 s,
which disappeared in the presence of a 100 mM KCl
gradient. This time course was similar to that re-
ported in the literature [21].
2.4. Thiamin uptake
BBMVs were incubated at 25‡C in a solution con-
taining (mM): 250 D-mannitol, 20 Tris^HEPES (pH
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7.5) and 1 WM [3H]T (speci¢c activity, 27.75 GBq/
mmol). 10 Wl of vesicle suspension was rapidly mixed
with 90 Wl of transport medium, and the incubation
was terminated by the addition of 3 ml of cold (0^
4‡C) stopping solution (150 mM NaCl, 1 mM Tris^
HEPES, pH 7.5). The amount of T radioactivity tak-
en up by the vesicles was radiometrically measured
after their separation by a rapid ¢ltration procedure
using cellulose nitrate micro¢lters (Micro¢ltration
System, Dublin, CA, USA; pore diameter, 0.65
Wm) previously saturated with unlabelled T [2].
Blanks were prepared in each experiment to evaluate
the radioactivity of [3H]T non-speci¢cally adsorbed
in the ¢lter. The values of blanks were subtracted
from the total radioactivity retained in the ¢lter. Ra-
diometric measurements were made using a Packard
Tri-Carb 2000 CA liquid scintillation counter (Pack-
ard Instrument, Downers Grove, IL, USA). Unless
stated otherwise, all uptake values were means
þ S.E.M. of at least triplicate determinations for
each of the ¢ve di¡erent vesicle preparations.
2.5. Short-time incubations
For 15 s incubation time a STRUMA short-time
incubation apparatus (Innovativ-Labor, Adliswill,
Switzerland) was used.
2.6. Chemical modi¢cation of BBMVs
Control vesicles were always processed in the same
conditions (time, pH, temperature and solutions) of
BBMVs treated with speci¢c blockers. Potential
changes in osmolarity due to the addition of chem-
ical modi¢ers, dithiothreitol (DTT), hydroxylamine
and free amino acids were prevented by adding an
isoosmotic amount of D-mannitol in control vesicle
incubating solutions. In protection experiments, free
amino acids were added in the incubation media in a
molar ratio 40% higher than that of blockers.
Moreover, to distinguish between negative results
and false negatives, when a chemical modi¢er did not
a¡ect T transport, higher concentrations of reagents
were utilized.
2.6.1. Carboxylic groups
Carboxylic groups were blocked with 20 mM
CMC or with 20 mM EDC following George and
Borders [22], or even with 5 mM WRK following
Dinur et al. [23].
2.6.2. Sulfhydryl groups
Sulfhydryl groups were blocked with 1.5 mM
DTNB [24] or with 1 mM PCMBS [25,26]. In some
experiments BBMVs pretreated with 1 mM PCMBS
were further incubated at 25‡C with 10 mM DTT, 20
mM HEPES^Tris (pH 7.0) and isoosmotic D-manni-
tol for 10 min [25].
2.6.3. Arginine residues
Arginine residues were blocked with PGO or NIN.
BBMVs were incubated with 50 mM PGO at 25‡C
[27^29] or with 1 mM NIN at 37‡C in the dark
[30,31] (see legend to Fig. 3). In some experiments,
BBMVs were incubated at 25‡C with 50 mM PGO
plus 70 mM L-histidine.
2.6.4. Histidine residues
Histidine residues were blocked with DEPC [32].
In some experiments, to test the speci¢city of the
reaction, BBMVs pretreated with 5 mM DEPC
were further incubated at 25‡C with 200 mM hydrox-
ylamine and 60 mM Tris^HEPES (pH 6.0) for 30
min, or with 10 mM DTT, 20 mM HEPES^Tris
(pH 6.5) and isoosmotic D-mannitol for 10 min
[26,33]. In addition, speci¢city was also evaluated
by treating BBMVs with 5 mM DEPC, 7 mM L-
arginine, 20 mM K2HPO4/KH2PO4 (pH 6.5) and
isoosmotic D-mannitol at 25‡C for 30 min.
2.6.5. Tyrosine residues
Tyrosine residues were blocked with 1 mM NBD-
Cl following Lin et al. [34] or with 5 mM NAI fol-
lowing Hori et al. [26].
2.6.6. Lysine residues
Lysine residues were blocked with 2 mM PLP fol-
lowing Haghighi et al. [35].
2.6.7. Serine residues
The e¡ect of the serine residue modi¢er SAL (10
mM) was tested following Han et al. [36]. For spe-
ci¢city, in some experiments BBMVs were treated at
25‡C with 10 mM SAL, 14 mM L-serine, 70 mM
Tris^HCl (pH 7.5) and isoosmotic D-mannitol for
20 min.
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Finally, the e¡ect of serine residue blockage on
T/H exchange was investigated using intestinal
BBMVs treated with SAL and preequilibrated (see
[3]) at pH 5 for 2 h at 4‡C and 20 min at 25‡C
in solutions containing (mM): 280 D-mannitol,
2 MgSO4, 20 MES^Tris, pH 5 (outwardly directed
H gradient) or 20 Tris^HEPES, pH 7.5 (H equi-
librium condition: controls). Both types of vesicles
were then incubated as indicated above, with a solu-
tion containing 1 WM [3H]T and (mM): 280 D-man-
nitol, 2 MgSO4, 20 Tris^HEPES, pH 7.5.
2.7. Washing procedures
The reaction of BBMVs with the chemical modi-
¢ers was stopped by adding 10 volumes of an ice
cold solution containing (mM): 250 D-mannitol, 20
Tris^HEPES, pH 7.5. The BBMVs were then centri-
fuged at 27 000Ug for 20 min, repeating the step
twice with 5 volumes of the same medium
[26,28,37,38]. After washing, the vesicles were imme-
diately utilized for uptake experiments.
2.8. Statistics
The signi¢cance of the di¡erences in the means
under di¡erent experimental conditions was eval-
uated using the following statistical methods: analy-
sis of variance (ANOVA) followed by Newman^
Keuls’s Q-test; Student’s t-test for paired data. All
statistical methods were carried out using a compu-
terized program [39].
Fig. 1. Time course of T uptake by rat intestinal and renal BBMVs treated with carboxylic group blockers EDC, CMC and WRK.
Vesicles treated with EDC, CMC and WRK (open squares) and control vesicles (¢lled squares) (see Section 2) were incubated at 25‡C
in a solution containing (mM): 250 D-mannitol, 20 Tris^HEPES, pH 7.5, and 1 WM [3H]T (speci¢c activity, 27.75 GBq/mmol). Sym-
bols represent mean þ S.E.M. of triplicate determinations for each of six di¡erent vesicle preparations. *P6 0.05 vs. controls (Student’s
t-test).
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2.9. Reagents
Unlabelled T chloride hydrochloride was obtained
from Prodotti Roche, Milan, Italy; EGTA and MES
hydrate (L-morpholino-ethanesulfonic acid) from Al-
drich Chimica, Milan, Italy. All other reagents were
supplied by Sigma Chimica, Milan, Italy, and BDH,
Poole, Dorset, UK.
2.10. Labelled compounds
[U-14C]D-Glucose (speci¢c activity, 10.8 GBq/
mmol) and [3H]T (speci¢c activity, 429.2 GBq/
mmol) were from Amersham Pharmacia Biotech
UK, Amersham, UK.
3. Results
In preliminary experiments, the possible alteration
of passive permeability due to vesicle treatment was
tested by measuring T uptake at 0‡C. Results showed
that passive permeability of T was una¡ected by all
chemical modi¢ers utilized (A. Verri, unpublished
data).
In treated and control vesicles from both kidney
and small intestine T uptake reached equilibrium al-
ready after 15 s incubation. This can be, at least in
part, ascribed to the presence of a binding compo-
nent that, in the absence of a pH gradient, is about
50% of total T uptake [3,11].
3.1. Carboxylic groups
All the carboxylic group blockers signi¢cantly in-
hibited total T uptake in both small intestinal and
renal BBMVs (Fig. 1). In renal BBMVs CMC and
EDC showed inhibition potencies higher than WRK.
3.2. Sulfhydryl groups
PCMBS produced on T transport an average inhi-
bition of 50% and 44% in renal and intestinal
BBMVs respectively, while DTNB was ine¡ective
(Fig. 2). Moreover, at 15 s incubation PCMBS inhi-
bition (65% þ 4 and 44% þ 14 for renal and small
intestinal vesicles respectively) of T uptake was re-
versed by further treatment of both types of vesicles
with 10 mM DTT, which can reverse the inhibition
of sulfhydryl groups. Percent inhibition of T uptake,
2.5 þ 3 and 0.6 þ 7 in renal and small intestinal
vesicles respectively, became negligible.
3.3. Arginine residues
In renal and small intestinal BBMVs T uptake was
inhibited by PGO to about 55% and 30% respectively
(Fig. 3); in contrast, NIN failed to inhibit. Since
NIN was ine¡ective and PGO could also interact
with histidine residues [40], in some experiments,
both renal and small intestinal vesicles were treated
with PGO in the presence or absence of 70 mM of
free L-histidine. The excess of L-histidine protected
Fig. 2. Time course of T uptake by rat intestinal and renal
BBMVs treated with the sulfhydryl group blocker PCMBS.
Vesicles treated with PCMBS (open squares) and control
vesicles (¢lled squares) (see Section 2) were incubated as de-
scribed in Fig. 1. Numbers of experiments for each symbol as
in Fig. 1. *P6 0.05 vs. controls (Student’s t-test).
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intestinal, but not renal vesicles (Fig. 4). Therefore,
the small intestinal BBMV inhibition was probably
caused by PGO reacting with histidine rather than
with arginine residues.
3.4. Histidine residues
Treatment of both renal and intestinal BBMVs
with DEPC signi¢cantly lowered T uptake by about
30% (Fig. 3). The inhibitory e¡ect of DEPC at 15 s
incubation (amounting to 53% þ 5 and 38% þ 6 for
renal and small intestinal vesicles respectively) was
not reversed by treatment with either 10 mM DTT
(i) or 200 mM hydroxylamine (ii), which are capable
of reversing the inhibition of sulfhydryl groups and
tyrosine residues respectively [26,33]. Using these re-
agents, percent inhibition was (i) 67% þ 5 and
31% þ 9, and (ii) 43% þ 4 and 53% þ 10 vs. respective
controls (vesicles incubated with DTT or hydroxyl-
amine without DEPC) for renal and small intestinal
vesicles respectively. Thus, under our experimental
conditions, DEPC did not react with sulfhydryl
groups and tyrosine residues, but only with histidine
residues.
To exclude any cross reaction of DEPC with L-
arginine, intestinal and renal BBMV were treated
with DEPC in the presence or absence of 7 mM of
free L-arginine: L-arginine protected only renal
vesicles (Fig. 4).
3.5. Tyrosine residues
T uptake by both renal and intestinal BBMVs was
signi¢cantly inhibited by NBD-Cl to about 60% up
Fig. 3. Time course of T uptake by rat intestinal and renal BBMVs treated with the L-arginine and L-histidine blockers PGO and
DEPC respectively. Vesicles treated with PGO or DEPC (open squares) and control vesicles (¢lled squares) (see Section 2) were incu-
bated as described in Fig. 1. Numbers of experiments for each symbol as in Fig. 1. *P6 0.05 vs. controls (Student’s t-test).
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to 1 min incubation; the intestinal uptake was also
reduced (by 25% decrease) at 5 min incubation (Fig.
5). In contrast, the preincubation of the vesicles with
the more speci¢c tyrosine blocker NAI did not in-
hibit T uptake [41,42].
3.6. Lysine and serine residues
SAL is a reagent for either lysine [43] or serine
residues [44]. SAL treatment signi¢cantly reduced re-
nal and intestinal vesicular T uptake by about 30^
40% (Fig. 5). In order to distinguish between L-lysine
and L-serine involvement, BBMVs were treated with
PLP, a lysine speci¢c blocker, in separate experi-
ments [35]. T vesicular transport was not a¡ected
by this treatment, showing that SAL speci¢cally in-
teracted with serine residues.
In other experiments, renal and intestinal BBMVs
were treated with SAL in the presence or in the ab-
sence of 14 mM free L-serine. L-Serine protected the
vesicles from SAL action and T uptake did not di¡er
signi¢cantly from that of vesicles treated with L-ser-
ine in the absence of SAL (controls). Percent inhibi-
tion accounted to only 2.8 þ 1 and 13 þ 4 in renal and
small intestinal vesicles respectively.
3.7. Serine residues and T/H exchange
The time course of T uptake by intestinal BBMVs
in the presence of an outwardly directed H gradient
(pHin 5:pHout 7.5) is shown in Fig. 6. As can be seen,
the overshoot uptake of T was virtually eliminated
by vesicle pretreatment with 10 mM SAL, indicating
that serine plays an essential role in the T/H ex-
change mechanism.
4. Discussion
Several reports indicate that a carrier-mediated
T transport system is present in the apical membrane
of the small intestine and kidney of mammals
[1^3,11,12,45^48], but little is known about the
molecular structure of the T transporter, and what
is known is con¢ned to the small intestine [12]. The
present study is the ¢rst approach towards identify-
ing the amino acids involved in the intestinal and
renal transmembrane T transporter by inducing
modi¢cations in the proteins of renal and small
intestinal rat BBMVs. The functional e⁄ciency of
our BBMV preparations, evaluated as the time
course of D-glucose uptake (A. Verri, unpublished
data), and their purity, evaluated as the enrichment
of alkaline phosphatase and K-activated phospha-
tase activities, were similar to those reported in the
literature and are considered sound for transport
studies.
Chemically, T is an organic cation which exists as
a monovalent cation at physiological pHs (range,
5^7.4) due to the presence of a quaternary nitrogen
at the 3 position of the thiazole moiety. At pHs high-
Fig. 4. E¡ect of L-histidine and L-arginine on T uptake by rat
intestinal and renal BBMVs treated with the L-arginine and
L-histidine blockers PGO and DEPC respectively. Vesicles,
treated with the blockers in the presence or absence of a large
amount of the free amino acid target, were incubated as de-
scribed in Fig. 1 for 15 s. Each bar represents mean þ S.E.M.
of at least triplicate determinations for each of four di¡erent
preparations. *P6 0.05 vs. intestinal vesicles treated with
PGO+L-histidine; **P6 0.05 vs. renal vesicles treated with
DEPC+L-arginine (ANOVA followed by Newman^Keuls’s
Q-test before transformation of the data as percent activity).
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er than 9.0, T is undissociated with the thiazole ring
open, whereas, at pHs lower than 4.0, T exists as a
divalent cation with nitrogen at the 1P position of the
pyrimidine moiety protonated [12]. These data sug-
gest the involvement of the carboxylic groups of
T transporters in T binding [12,13].
Our results showed that carboxylic blockers inhib-
ited either small intestinal or renal T uptake by
about 50% (Fig. 1). Since the carbodiimides CMC
and EDC as well as the WRK are hydrophilic com-
pounds [31], which cannot cross biological mem-
branes, it can be assumed that T can bind its trans-
porter at the external cellular side. Moreover, as
previously suggested [12,13], the quaternary nitrogen
of the T thiazole moiety is probably responsible for
the binding of T to the carboxylic groups of T trans-
porters, it being the only quaternary nitrogen present
at physiological pH.
By using DTNB and PCMBS, the presence of sulf-
hydryl groups in the molecular structure of the
T transporter could be assessed. Only PCMBS inhib-
ited the time course of T uptake in both types of
vesicles (Fig. 2). The inhibition was speci¢c, since
DTT was able to remove the linkage with sulfhydryl
groups, suggesting that the sulfhydryl blocker
PCMBS probably inhibited the functional sulfhydryl
groups of the T transporter.
DTNB, another sulfhydryl groups blocker, was
unable to inhibit T uptake since it is an aromatic
disul¢de with a greater steric impediment, preferring
to react with denatured proteins [49], which is not
our case. An important role of sulfhydryl groups was
observed for organic cation transporters [25,50] and
for H/ATPase [51]. Interestingly, our results would
be in keeping with the hypothesis that T could cross
the biological membranes as a thiazolium ring
Fig. 5. Time course of T uptake by rat intestinal and renal BBMVs treated with the L-tyrosine and L-serine blockers NBD-Cl and
SAL respectively. Vesicles treated with NBD-Cl and SAL (open squares) and control vesicles (¢lled squares) (see Section 2) were incu-
bated as described in Fig. 1. Numbers of experiments for each symbol as in Fig. 1. *P6 0.05 vs. controls (Student’s t-test).
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opened thiol species, interacting with membrane sulf-
hydryl groups during translocation [52^55].
The role played by arginine and histidine residues
in the structure of T transporters was also investi-
gated by using either PGO or DEPC. Both blockers
inhibited renal and intestinal T uptake (Fig. 3). Spe-
ci¢city experiments, while excluding any cross reac-
tion by DEPC with sulfhydryl groups and tyrosine
residues, suggested that PGO in the small intestinal
BBMVs blocked histidine rather than arginine resi-
dues. In fact, vesicles preincubated with PGO in the
presence of an L-histidine excess normally took up T
(Fig. 4). Vice versa, the presence of an L-arginine
excess during DEPC treatment could protect renal
but not small intestinal BBMVs (Fig. 4). Taken to-
gether, these results suggest that the T transporter
has essential arginine or histidine residues in the kid-
ney and in the small intestine BBMVs respectively.
Some H driven transport systems (symports and
antiports), similar to the renal and small intestinal
T/H antiport, possess essential histidine or arginine
residues for their functioning [32,56]. Probably, argi-
nine and/or histidine are located at the H binding
sites rather than at the organic and inorganic com-
pound binding sites [26,56^59]. As previously sug-
gested [12,13], the nitrogen at the 1P position of the
pyrimidine moiety of T can react with a positive
charge present in the amino acid sequence of the
transporter. At physiological pH, both histidine
and arginine residues meet this requirement [60].
Blockers NBD-Cl and NAI allowed us to investi-
gate the role of tyrosine residues in the T transport
system. T uptake was inhibited by NBD-Cl, but not
by NAI (Fig. 5), an apparent discrepancy that could
be explained by considering the speci¢city and the
sensitivity of the two tyrosine blockers. NBD-Cl po-
tentially can react with tyrosine, lysine and cysteine
residues [42]. In our experiments, NBD-Cl interac-
tion with L-lysine residues could be excluded, since
at pH 7.4, the reaction of NBD-Cl with the amino
group is almost negligible, taking place at pHs higher
than 8 [61]. In addition, BBMV treatment with PLP,
a speci¢c lysine blocker, did not modify T transport.
Thus, the sites chemically modi¢ed by NBD-Cl could
only be tyrosine and cysteine residues. Since NAI did
not inhibit T uptake, the conclusion can be reached
that NBD-Cl reacted with cysteine residues. This hy-
pothesis was con¢rmed following the use of the sulf-
hydryl speci¢c reagent PCMBS, which signi¢cantly
inhibited T uptake in both renal and small intestinal
vesicles (Fig. 2). However, it has previously been
shown that NAI is the most selective tyrosine re-
agent, even though its inhibitory potency appears
to be lower than that of NBD-Cl [41,42].
SAL, a blocker of serine residues, reduced T up-
take in both renal and small intestinal BBMVs (Fig.
5). The presence of a large amount of free L-serine
during SAL treatment protected the vesicles, indicat-
ing strong competition for SAL between exogenous
free L-serine and the transporter sites modi¢ed by
SAL. However, SAL inhibition could not be ascribed
to the blockage of L-lysine residues, the other amino
acid target for SAL [36,43,44,62], since PLP, a spe-
ci¢c lysine blocker, was ine¡ective. It should be em-
phasized that the blockage of serine residues also
impeded T/H exchange in intestinal (and in renal,
A. Verri, unpublished data) BBMVs as was shown
by the disappearance of the typical overshoot [3],
Fig. 6. Time course of T/H exchange (under pH gradient,
pHin 5:pHout 7.5) in rat intestinal BBMVs. Vesicles treated with
SAL and controls (see Section 2) were preincubated (2 h at 4‡C
and 20 min at 25‡C) in a medium containing (mM): 280 D-
mannitol, 2 MgSO4, 20 MES^Tris, pH 5. Vesicles were then in-
cubated at 25‡C with a solution containing (mM): 280 D-man-
nitol, 2 MgSO4, 20 Tris^HEPES, pH 7.5 and 1 WM [3H]T (spe-
ci¢c activity, 27.75 GBq/mmol). Symbols represent
mean þ S.E.M. of at least triplicate determinations for each of
¢ve di¡erent preparations. *P6 0.05 vs. control (Student’s t-
test).
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observed in untreated vesicles in the presence of an
outwardly directed pH gradient (Fig. 6).
In conclusion, carboxyl groups, sulfhydryl groups
and serine residues should be essential for T trans-
port in both renal and small intestinal BBMVs. In
addition, the renal transporter has essential arginine
and the small intestinal histidine residues. The di¡er-
ences in the sensitivity toward the chemical modi¢ers
could also indicate that the renal transporter of T is
di¡erent from the transporter present in small intes-
tine. Thus, the existence of di¡erent transporters
could account for the di¡erences in the transport
capacity and speci¢city previously observed in kidney
and small intestine [3,11].
It is interesting to compare our results on rats with
those by Katsura et al. [50], who applied our exper-
imental approach to the same animals but with tet-
raethylammonium (TEA) instead of T as an organic
cation. Here, the renal BBMV transporter of TEA
was found to possess the essential carboxyl and sulf-
hydryl groups and histidine and arginine residues.
Thus the renal T transporter would appear to be
di¡erent from the renal organic cation transporter.
However, no de¢nitive conclusions can be drawn,
since our study is much more extensive, including
also serine, tyrosine and lysine residues, which were
not investigated by Katsura et al. [50].
It must be emphasized that, in general, the results
of experiments with chemical blockers have often
been found to have a larger in£uence on activity
than with mutagenesis, probably because of the steric
e¡ects caused by the relatively bulky labeling re-
agents [63,64]. Thus the results reported here will
be fully appreciated only after the amino acid se-
quences of the T intestinal and renal transporters
have been found and mutagenesis experiments per-
formed. For example, the involvement of essential
arginine residues in the Na dependent renal trans-
port of glucose was previously suggested by Strevey
et al. [65] by using PGO treated BBMVs. Cloned
sequences for Na dependent glucose transporters
SGLT1 and SGLT2 con¢rmed important arginine
groups in at least two di¡erent domains [66].
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